|
• November,
2000 • September,
2001 Expired Lessons • May,
2000 |
Release Date: September 2001 Last Review Date: August 2001 Expiration Date: September 30, 2002 Target Audience: Ophthalmologists Statement of Need: Glaucoma is one of the leading causes of blindness worldwide and is estimated as affecting 3 million people in the United States alone accounting for over 4.5 million visits to ophthalmologists' each year. These figures will only increase in the coming years. A full understanding of this disease, its diagnosis and treatment options, is necessary to efficiently treat patients with chronic open-angle glaucoma. This handbook discusses the definition of glaucoma and its treatment options, the safety and efficacy of medications available as well as the current and future surgical procedures. Learning Objectives:
Faculty/Editorial Board: Richard F. Brubaker, MD; Louis B. Cantor, MD; David L. Epstein, MD; Ronald L. Gross, MD; L. Jay Katz, MD; Robert J. Noecker, MD; Steven T. Simmons, MD; Joel S. Schuman, MD Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine and Review of Ophthalmology. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality, and scientific integrity of this CME activity. Designation Statement: The Postgraduate Institute for Medicine designates this educational activity for a maximum of four (4) hours in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity. Disclosure Statement: Dr. Brubaker Dr. Brubaker has disclosed that he is a consultant for Allergan, Inc. Dr. Cantor has received research support from Alcon, Allergan, Merck, Novartis and Pharmacia. He is on the Speaker's Bureau for Alcon, Allergan and Merck. Dr. Epstein has noted that any financial interests he has are through Duke University. Dr. Gross has disclosed that he is a consultant for Alcon, Allergan, Novartis and Pharmacia. He has received research support from Alcon, Allergan, Merck, Novartis and Pharmacia. Dr. Gross is on the Speaker's Bureau for Alcon, Allergan and Pharmacia. Dr. Katz has received research support from and is on the Speaker's Bureau for Allergan, Merck, Novartis and Pharmacia. Dr. Noecker has disclosed that he is a consultant for Allergan, Coherent, Ciba, Merck and Pharmacia. He has received research support from Allergan, Coherent, Merck, and Pharmacia. Dr. Noecker is on the Speaker's Bureau for Allergan. Dr. Simmons has received research support from Alcon, Allergan, Merck, Novartis and Pharmacia. He is on the Speaker's Bureau for Allergan, Alcon, Merck and Novartis Dr. Schuman has received research support and is on the Speaker's Bureau for Allergan, Merck, Novartis, and Pharmacia. Postgraduate Institute
for Medicine has a conflict of interest policy that requires course
faculty to disclose any real or apparent commercial financial affiliations
related to the content of their presentations/materials. It is not
assumed that these financial interests or affiliations will have
an adverse impact on faculty presentations; they are simply noted
here to fully inform participants.
Click here to participate in this CME program.
|
